# Outcome Maturity Acceleration Review 001

Objective: determine how AEGIS can most efficiently increase validated outcome accumulation using existing capabilities.

Scope: existing journal reviews, root-cause review, weekly learning report, paper position ledgers, sleeve performance truth artifacts, outcome maturity reviews, validation sample summaries, hypothesis decision policy artifacts, research allocation recommendation artifacts, and sleeve throughput reviews.

This review adds no architecture, schemas, mechanisms, DES systems, DES-Lite systems, runtime truth changes, trade advice, candidates, sleeve changes, or capital allocation.

## 1. Executive Summary

Outcome maturity is the highest-leverage AEGIS bottleneck. The evidence does not show an absence of paper activity; it shows that paper activity has not yet become enough closed, usable, distributed validation evidence.

The strongest validated-outcome path is existing paper-position follow-through. On 2026-06-03, the paper position ledger had 63 positions, 51 open positions, and 12 closed positions. Validation samples had 63 total samples, 12 included closed or resolved outcomes, and 51 excluded samples. Statistical sufficiency showed 9 hypotheses, 8 underpowered, 1 validation-ready, and 0 validated. Sleeve evidence certification showed 5 evaluated sleeves, all UNDERPOWERED, with 1 BUILDING_SAMPLE and 4 ZERO_SAMPLE.

The fastest useful outcome evidence is likely to come from existing open paper positions, especially `C2_TREND_EQ_PRIMARY_V1`, because it already has the only building sample and all 12 closed sleeve-level outcomes in the 2026-06-03 evidence. That does not make it capital-ready or positive; it only makes it the most mature existing evidence stream. The next useful learning comes from converting zero-sample but paper-active sleeves into first closed samples.

## 2. Why Outcome Samples Are Underpowered

Outcomes are underpowered because most paper positions remain open. The 2026-06-03 ledger had 63 positions and 51 open positions. The 2026-06-04 ledger had 63 positions and 58 open positions. Validation samples stayed dominated by excluded open samples: 51 excluded on 2026-06-03 and 58 excluded on 2026-06-04.

Outcomes are concentrated in one sleeve. Sleeve performance truth and sleeve evidence certification for 2026-06-03 show all 12 closed positions came from `C2_TREND_EQ_PRIMARY_V1`. The other evaluated sleeves, `C2_CROSS_ASSET_TREND_V1`, `C2_MEAN_REVERSION_EQ_V1`, `C2_OIL_SHOCK_REVERSAL_V1`, and `C2_VOL_INCOME_DEFINED_RISK_V1`, had paper trades but 0 closed evidence-certification samples.

Candidate scarcity and conversion bottlenecks slow outcome accumulation. Root Cause Review 001 found 42 raw signals, 1 generated candidate, and 1 paper position on 2026-06-03. Journal Review 001 and Journal Review 002 refine that interpretation: most raw-signal rejection was expected portfolio suppression, while certification and paper-path bottlenecks still prevent raw activity from becoming validation samples.

Paper-path and data readiness gaps keep some hypotheses from being measurable. Hypothesis decision policy repeatedly classified some rows as REDESIGN or NEEDS_DATA, with reason codes such as `NO_CANDIDATE_FLOW`, `NO_OBSERVATION_FLOW`, `NO_PAPER_PATH`, `IMPLEMENTATION_INCOMPLETE_OR_NO_PAPER_PATH`, and `DATA_QUALITY_BLOCKED`.

Capital review is not currently useful for outcome maturity. Research quality, hypothesis decision policy, and research allocation recommendation artifacts showed 0 ready for capital review. Outcome accumulation should remain a research-evidence task, not an allocation task.

## 3. Top 5 Outcome Acceleration Actions

### 1. Continue deterministic outcome validation on existing open paper positions

- Action: Re-run existing paper outcome closure, outcome validation, validation sample, statistical sufficiency, and sleeve evidence certification flows as existing paper positions mature.
- Expected impact: Highest. The largest near-term source of new validated samples is the 51 open positions on 2026-06-03 and 58 open positions on 2026-06-04.
- Evidence: Paper position ledger showed 63 positions and 51 open on 2026-06-03; validation samples showed 51 excluded samples; outcome registry showed 51 open outcomes.
- Risk: Low if strictly read-only and deterministic. Risk rises if anyone tries to force closure, override exit rules, or treat open positions as outcomes.
- Estimated effort: Low. This uses existing ledgers and validation artifacts.

### 2. Prioritize evidence follow-through for `C2_TREND_EQ_PRIMARY_V1`

- Action: Treat `C2_TREND_EQ_PRIMARY_V1` as the primary existing outcome-learning stream and keep its validation, sufficiency, and evidence-certification artifacts current.
- Expected impact: High. It is the only sleeve with closed samples and the only building sample in sleeve evidence certification.
- Evidence: On 2026-06-03, sleeve evidence certification showed `C2_TREND_EQ_PRIMARY_V1` with 12 closed positions, sample status BUILDING_SAMPLE, and evidence status UNDERPOWERED. Hypothesis outcome ledger showed `HYP_LARGE_CAP_EQUITY_MOMENTUM_20_60D_V1` with all 12 usable validation samples.
- Risk: Medium. This can deepen the sample fastest but also worsens concentration if treated as the only learning stream.
- Estimated effort: Low. It requires evidence follow-through, not new trading behavior.

### 3. Convert zero-sample paper-active sleeves into first closed samples

- Action: Monitor existing paper-active sleeves with 0 closed samples until deterministic close conditions create valid outcomes.
- Expected impact: Medium-high. First closed samples for zero-sample sleeves improve distribution, not just count.
- Evidence: On 2026-06-03, `C2_CROSS_ASSET_TREND_V1` had 5 paper trades, `C2_MEAN_REVERSION_EQ_V1` had 2, `C2_OIL_SHOCK_REVERSAL_V1` had 1, and `C2_VOL_INCOME_DEFINED_RISK_V1` had 2, but sleeve evidence certification showed all four as ZERO_SAMPLE.
- Risk: Low if the action is monitoring and validation only. Risk is high if AEGIS changes exits or creates new positions to manufacture outcomes.
- Estimated effort: Low to medium. The evidence already exists, but useful outcome accumulation depends on existing positions reaching deterministic close conditions.

### 4. Resolve data and authority blockers that prevent existing evidence from counting

- Action: Use existing data-action routing, integrity warnings, and evidence-contract checks to keep required evidence discoverable and current.
- Expected impact: Medium. It does not create outcomes, but prevents existing outcomes from being blocked, invisible, or excluded.
- Evidence: Journal Review 002 identifies evidence contract and certification resolution as a top bottleneck. KNW_0019 shows verified-graph blockers can come from evidence-ID contract mismatches even when artifacts exist. 2026-06-04 sleeve performance truth was blocked by missing authority, and daily research integrity reported graph-readiness blockers.
- Risk: Low if limited to evidence discovery, source freshness, and contract alignment. Risk rises if blocker repair mutates runtime truth or changes paper/trading behavior.
- Estimated effort: Medium. It requires careful evidence triage but no architecture expansion.

### 5. Use candidate conversion diagnostics to focus on paper-observation eligibility, not raw volume

- Action: Review existing candidate diagnostics by conversion stage: raw signal, expected portfolio suppression, certification status, valid candidate contract, paper observation, and closed outcome.
- Expected impact: Medium. It prevents effort from going toward raw candidate volume that does not increase validation samples.
- Evidence: Journal Review 001, Journal Review 002, and Root Cause Review 001 show 42 raw signals produced 1 generated candidate and 1 paper position on 2026-06-03, while most rejected signals were expected portfolio suppression and 2 were non-certified snapshot bottlenecks.
- Risk: Low. The main risk is misclassifying expected governance suppression as a defect and chasing the wrong repair.
- Estimated effort: Medium. It is analysis-heavy but uses existing diagnostics.

## 4. Actions To Avoid

- Do not expand architecture, add schemas, add mechanisms, or introduce DES/DES-Lite systems to solve outcome maturity.

- Do not create trade advice, new candidates, sleeve changes, capital allocation, or runtime truth changes.

- Do not force outcome closure. Open paper positions are not validated outcomes until deterministic close conditions and existing validation artifacts support them.

- Do not treat candidate volume, raw signals, paper-trade count, or graph readiness as outcome maturity.

- Do not prioritize capital review while research quality and allocation artifacts show 0 capital-review-ready rows.

- Do not spend outcome-maturity effort on sleeves with no candidate flow, no paper path, or unresolved data source before existing paper-active sleeves produce first closed samples.

- Do not treat `C2_TREND_EQ_PRIMARY_V1` as broadly proven. It is the highest-priority evidence stream because it has samples, not because it is validated or capital-ready.

## 5. High-Priority Sleeves For Outcome Learning

1. `C2_TREND_EQ_PRIMARY_V1`
Reason: highest immediate outcome-learning value. It had 53 paper trades, 12 closed positions, BUILDING_SAMPLE status, and all sleeve-level closed samples on 2026-06-03.
Use: continue validation and sufficiency follow-through on existing positions.

2. `C2_CROSS_ASSET_TREND_V1`
Reason: paper-active with 5 paper trades and 5 outcome rows in the 2026-06-03 scorecard, but 0 closed certification samples. It can improve distribution if existing positions close.
Use: monitor existing paper positions through deterministic closure and validation.

3. `C2_MEAN_REVERSION_EQ_V1`
Reason: paper-active with 2 paper trades and 2 outcome rows, but ZERO_SAMPLE status.
Use: convert existing paper activity into first closed validation samples when conditions allow.

4. `C2_VOL_INCOME_DEFINED_RISK_V1`
Reason: paper-active with 2 paper trades and 2 outcome rows, but ZERO_SAMPLE status.
Use: same as mean reversion: outcome follow-through, not new position creation.

5. `C2_OIL_SHOCK_REVERSAL_V1`
Reason: has 1 paper trade and 1 outcome row, and generated-hypothesis artifacts show paper observation flow reached but outcome readiness blocked by close condition not met.
Use: monitor existing paper observation until deterministic close condition is met; do not force candidate or outcome creation.

## 6. Low-Priority Sleeves For Outcome Learning

- `C2_DEFENSIVE_TAIL_V1`: low immediate outcome-learning priority because decision artifacts cite stalled candidate generation, no observation flow, no paper path, and implementation or paper-path repair needs.

- `C2_INTENT_SIMULATOR_V1`: low immediate priority for validated outcome accumulation because it has no candidate flow, no observation flow, no paper path, and redesign classification.

- `C2_MARKET_NEUTRAL_SPREAD_V1`: low immediate priority for the same reason: stalled candidate generation and no paper path in decision artifacts.

- `C2_EVENT_DISLOCATION_V1`: low immediate outcome priority despite high candidate-yield signals because the evidence cites no observation flow, no paper path, and 0 usable validation samples. It may be an investigation priority, but not the fastest existing outcome-maturity path.

- `ehp_macro_calendar_fixture`: low immediate priority because macro calendar readiness needs a source and data quality is blocked. It should not be repaired by fabricating macro events or creating paper sleeve behavior.

## 7. Recommended Next Step

Run a read-only outcome follow-through review on existing open paper positions, centered on `C2_TREND_EQ_PRIMARY_V1` and the four paper-active zero-sample sleeves.

The review should answer only these questions using existing artifacts:
- Which open paper positions are eligible for deterministic closure?
- Which excluded validation samples can become included without changing rules?
- Which sleeves remain ZERO_SAMPLE solely because positions are still open?
- Which blockers are evidence-discovery or data-authority issues rather than trading or architecture issues?

This is the highest-leverage next step because it targets the binding constraint identified by Journal Review 002 and Root Cause Review 001: outcome maturity needs more closed, usable, distributed validation samples, not more architecture or capital review.
